Today: 21 July 2026
Nestle stock faces Monday test after France probes baby deaths tied to recalled formula
25 January 2026
1 min read

Nestle stock faces Monday test after France probes baby deaths tied to recalled formula

Zurich, Jan 25, 2026, 19:58 CET — Market closed.

  • On Friday, Nestle shares ended the session down 1.0%, closing at 72.47 Swiss francs.
  • France is investigating two infant deaths linked to formula that had been subject to precautionary recalls.
  • Traders await investigative findings due in the coming days, along with Nestle’s results on Feb. 19.

Nestle shares face pressure as Swiss markets open Monday, following French authorities launching investigations into the deaths of two infants linked to baby formula from precautionary recalls.

The Swiss food group’s shares ended the session down 0.98%, closing at 72.47 Swiss francs. This price point could expose the stock to fresh headline-driven swings once trading restarts.

This is critical now since infant nutrition hinges on trust, and the incident keeps Nestle under scrutiny while it struggles to contain an expanding formula recall. The longer the problem drags on, the more investors prepare for higher expenses, sales declines, or increased regulatory pressure.

This also comes before Nestle’s next big event: the full-year results set for Feb. 19.

French investigators are looking into whether the deaths are connected to the products, but the health ministry says no causal link has been found yet. The recalls involve potential contamination with cereulide, a toxin known to cause nausea and vomiting.

Nestle rejected any connection between its products and the deaths, stating in an email: “at this stage nothing indicates any link between these tragic events and the consumption of our products.” Reuters

On Friday, shares moved within a tight band from 71.96 to 73.07 francs but closed down, market data show. This limited fluctuation hints that investors haven’t sharply adjusted their risk outlook — at least not so far.

The problem isn’t limited to Nestle. Lactalis has pulled infant milk from shelves in several countries, while Danone has flagged concerns over a batch destined for Singapore. This points to a wider supply-chain issue in the sector.

Traders will be closely monitoring any updates from prosecutors and ministries in the week ahead, looking for clues on whether the recall perimeter will expand or hold steady. France’s farm ministry said it expects results from an initial judicial inquiry within the next 10 days.

Macro factors remain in play. On Monday, Switzerland’s central bank will release “important monetary policy data,” a report likely to influence the franc and shape rate expectations crucial to global giants such as Nestle. Swiss National Bank Data Portal

The path is straightforward. Should investigators come up empty and the recall fade, the stock might shift back to focusing on rates and earnings forecasts. But if a connection is proven, legal risks and reputational harm could escalate quickly, prompting investors to factor in a prolonged drop in volumes.

Next on the docket: official findings from France expected within the 10-day timeframe, followed by Nestle’s February 19 earnings release. Management will need to address the financial fallout and confirm if the disruption is under control.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors. Follow Khadija Saeed on Google News.

Stock Market Today

  • Monarch Casino (MCRI) Tops Q2 Expectations for Earnings and Sales
    July 20, 2026, 8:22 PM EDT. Monarch Casino (MCRI) posted Q2 earnings of $1.78 per share, above forecasts of $1.75, while revenue came in at $142.6 million, ahead of the anticipated $139.8 million. Profit improved from $1.44 per share a year earlier, producing a +1.71% earnings surprise. The company has beaten EPS projections in three of the last four quarters. Shares are up 28.6% so far this year, compared with an 8.9% rise for the S&P 500.
Exxon stock price: XTO’s Eagle Ford sale push puts XOM in play ahead of key week
Previous Story

Exxon stock price: XTO’s Eagle Ford sale push puts XOM in play ahead of key week

Intuitive Surgical stock price: what to watch Monday after ISRG’s 2026 da Vinci outlook and tariffs hit focus
Next Story

Intuitive Surgical stock price: what to watch Monday after ISRG’s 2026 da Vinci outlook and tariffs hit focus

Go toTop